OMER: רווח למניה בשנים עשר החודשים האחרונים Omeros Corporation

Omeros Corporation (OMER) is pursuing expansion through drugs for the treatment of rare vascular pathologies. This model relies on R&D patent protection, which ensures high margins during mass synthesis. The 12-month earnings per share history visualizes this trend, where 1.44 represents the latest level. However, revenue volatility and development costs render cash flows unstable.
OMER (Omeros Corporation): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Omeros Corporation is focusing its development on bringing drugs for the therapy of rare vascular pathologies to market, which makes the trailing twelve-month earnings per share a key indicator of R&D investment efficiency. This metric is calculated by dividing the total annual net income by the total number of shares, allowing investors to assess the real return on each share of ownership and the stability of the capital.